Arg⁹⁷² Insulin Receptor Substrate-1 Inhibits Endothelial Nitric Oxide Synthase Expression in Human Endothelial Cells by Upregulating MicroRNA-155
Overview
Authors
Affiliations
The dysregulation of nitric oxide (NO) synthesis attributable to the abnormal expression/activity of endothelial NO synthase (eNOS) is considered to be a major characteristic of insulin-resistant states, as well as an essential contributor to the pathogenesis of cardiovascular diseases. The Arg972 insulin receptor substrate-1 (IRS-1) is associated with insulin resistance. In the present study, we investigated the association between Arg972 IRS-1 and eNOS expression/activity in human subjects and in primary cultures of human endothelial cells. Data from 832 human subjects revealed that heterozygous and homozygous Arg972 IRS-1 carriers had significantly lower levels of plasma eNOS and nitrite/nitrate than the homozygous wild-type (WT) IRS-1 carriers. Human umbilical vein endothelial cells (HUVECs) established from delivering mothers expressing heterozygous Arg972 IRS-1 had significantly lower eNOS expression/activity and higher miR-155 levels than those expressing WT homozygous IRS-1. The overexpression of IRS-1 and Arg972 IRS-1 in the HUVECs, respectively, decreased and increased the miR-155 expression level. In addition, the overexpression of IRS-1 in the HUVECs significantly increased eNOS expression; this effect was reversed by transfection with mature miR-155 mimic or treatment with the selective phosphatidylinositol-3 kinase (PI3K) inhibitor, BKM120. On the other hand, the overexpression of Arg972 IRS-1 markedly decreased eNOS expression and this effect was reversed by transfection with antagomir-155. On the whole, our in vivo data demonstrate that Arg972 IRS-1 is associated with decreased plasma eNOS and nitrite/nitrate levels in human subjects. Our in vitro data demonstrate that Arg972 IRS-1 inhibits eNOS expression in human endothelial cells by upregulating miR-155 expression through the impairment of PI3K signaling. The present study provides new insight into the pathophysiological role of Arg972 IRS-1 in cardiovascular diseases.
Puschel G, Klauder J, Henkel J J Clin Med. 2022; 11(15).
PMID: 35955975 PMC: 9369133. DOI: 10.3390/jcm11154358.
Zong J, Tang Y, Wang T, Ullah I, Xu K, Wang J J Am Heart Assoc. 2022; 11(16):e025058.
PMID: 35929455 PMC: 9496289. DOI: 10.1161/JAHA.121.025058.
Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage.
Nigro C, Leone A, Raciti G, Longo M, Mirra P, Formisano P Int J Mol Sci. 2017; 18(1).
PMID: 28106778 PMC: 5297820. DOI: 10.3390/ijms18010188.
The impact of insulin resistance on the kidney and vasculature.
Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Haring H Nat Rev Nephrol. 2016; 12(12):721-737.
PMID: 27748389 DOI: 10.1038/nrneph.2016.145.
miR-155 Deletion in Female Mice Prevents Diet-Induced Obesity.
Gaudet A, Fonken L, Gushchina L, Aubrecht T, Maurya S, Periasamy M Sci Rep. 2016; 6:22862.
PMID: 26953132 PMC: 4782173. DOI: 10.1038/srep22862.